Bluefin BioMedicine Revenue and Competitors
Estimated Revenue & Valuation
- Bluefin BioMedicine's estimated annual revenue is currently $1.6M per year.
- Bluefin BioMedicine's estimated revenue per employee is $155,000
Employee Data
- Bluefin BioMedicine has 10 Employees.
- Bluefin BioMedicine grew their employee count by 0% last year.
Bluefin BioMedicine's People
Name | Title | Email/Phone |
---|---|---|
1 | SVP and Head Research and Development | Reveal Email/Phone |
2 | Sr Director, Clinical Operations | Reveal Email/Phone |
3 | Principal Scientist | Reveal Email/Phone |
4 | Bluefin Biomedicine - Head Business Development | Reveal Email/Phone |
Bluefin BioMedicine Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Bluefin BioMedicine?
Founded in 2016, Bluefin BioMedicine is a privately held company focused on the detection of novel cancer antigens and the development of next-generation medicines for the treatment of cancer. We are using proprietary, cutting-edge protein detection methods to interrogate complex tumor specimens and discover differentially expressed cancer antigens that can be targeted with antibody therapies. Our focus is on cancers with clear unmet medical need and building a robust portfolio of therapeutic candidates that address those needs.
keywords:N/AN/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.8M | 10 | -9% | N/A |
#2 | $1.7M | 11 | 0% | N/A |
#3 | $1.7M | 11 | 10% | N/A |
#4 | $0.9M | 11 | 22% | N/A |
#5 | $1.7M | 11 | -8% | N/A |